Dr Marco Gerlinger's team investigates the impact of genetic and non-genetic intra-tumour heterogeneity on disease progression and how systemic therapies re-shape cancer genomic landscapes.
Dr Marco Gerlinger develops new tools to detect and track the evolution of cancer cells within tumours and better therapies which prevent the evolution of drug resistance. He holds an Honorary Consultant Medical Oncologist position at The Royal Marsden NHS Foundation Trust, where he treats patients with gastrointestinal cancers.